Infection
Category VIEW ALL
Antibody-Based Inhibition of Uropathogenic E. coli Adhesion
The technology offers innovative antibody compositions that target the FimH adhesin of uropathogenic E. coli, preventing bacterial adhesion and biofilm formation.
Bikunin Biomimetic with Anti-Inflammatory and Antiviral Activity
The solution is a serine protease inhibitor, bikunin, that plays a role in controlling the early immune response to Influenza A virus.
Long-Acting Injectable Colloidal Formulations for HIV Integrase Inhibitors
This technology offers injectable formulations of HIV integrase inhibitors designed for extended drug release, enabling less frequent dosing and improved patient adherence in both treatment and prevention settings.
Long-Acting Injectable Drug Combinations for Sustained Cancer Therapy and Beyond
These innovations enable the formulation of long-acting injectable drug combinations, including chemotherapies, by transforming short-acting agents into stable, sustained-release nanoparticles or suspensions. The technologies offer a platform approach to improve treatment adherence, reduce dosing frequency, and enhance drug exposure at disease sites.
Multi-Functional Mucosal Vaccine Platform for Enhanced Immunogenicity
A novel mucosal vaccine platform designed to improve mucosal immune responses against infectious diseases through targeted delivery and prolonged stability.
Multivalent and De Novo Miniprotein Inhibitors Targeting SARS-CoV-2 Spike Protein
This suite of protein-based inhibitors is designed to block SARS-CoV-2 infection by binding to the virus’s spike protein with high precision. The technologies include multivalent constructs and de novo miniproteins that neutralize diverse variants and offer potential for intranasal delivery.
Novel Nanoparticle Immunogens for Influenza Vaccines
This technology offers a new approach to influenza vaccines using computationally designed nanoparticle immunogens that elicit potent, neutralizing antibodies against influenza viruses.
Secretion-Optimized Protein Nanoparticles for Eukaryotic Expression and Genetic Delivery
This technology offers innovative protein nanoparticles designed for efficient secretion in eukaryotic cells, enhancing genetic delivery and therapeutic applications.
Stable Drug-Polymer Particles for Sustained Release in Multi-Drug Formulations
This technology enables the formation of stable, co-assembled drug-polymer particles that deliver multiple antiviral agents with sustained release properties. The method supports simplified dosing and improved drug stability for combination therapies.
Targeted Protein Degradation in Bacteria Contributes to Antibiotic Efficacy
The solution is a method to develop new antibiotic proteolysis targeting chimeras (PROTACs) that target proteins of interest for degradation in bacteria to counteract antibiotic resistance.
Treponema Pallidum-Specific Aptamers for Syphilis Diagnostics
The solution is the development of Treponema pallidum-specific aptamers to be used in accurate point-of-care diagnostic assays for syphilis.